PlainPharmaWatch

CMS Open Payments · Program Year 2024

Fujirebio Diagnostics, Incorporated

Fujirebio Diagnostics, Incorporated reported $2,245,804.41 across General Payments, Research, and Ownership to 10 physicians and teaching hospitals across 16 transactions.

See the rankings → How this is sourced
$2.2M
All-tracks total
16
Transactions
10
Recipients
−$119.0K
General Payments vs PY2023

Fujirebio Diagnostics, Incorporated reported $2,245,804.41 across all CMS Open Payments tracks (General + Research + Ownership) to 10 physicians and teaching hospitals in Program Year 2024 - ranking #424 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,144,486.78, averaging $224.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer fujirebio-diagnostics-incorporated Fujirebio Diagnostics, Incorporated

$2.2M · #424/1,925 · 0.0% industry · PY2024

  • TOT $2.2M
  • RANK #424
  • SHARE 0.0%
  • TXN 16
  • RCP 10
  • CAT 2
  • GEN $2.1M
  • ΔGEN −$119.0K
  • TOP1 97.4%
  • PY 2024

Volume peers

Nearest volume peer: Orchard Therapeutics North America ($2.2M)

Ceribell, Inc.$2.3MFujirebio Diagnostics, Incor…$2.2MOrchard Therapeutics North A…$2.2MNew World Medical,inc.$2.2MSmarter Devices, LLC$2.2M
All-tracks payment totals near Fujirebio Diagnostics, Incorporated (CMS Open Payments PY2024)

Fujirebio Diagnostics, Incorporated sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Fujirebio Diagnostics, Incorporated's CMS-reported General Payments decreased by $119.0K (−5.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: FUJIREBIO DIAGNOSTICS, INCORPORATEDPY2023: FUJIREBIO DIAGNOSTICS, INCORPORATEDPY2024: Fujirebio Diagnostics, Incorporated. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$2.3MPY2024$2.1M
PY2023
$2,263,466.69
PY2024
$2,144,486.78

What the Data Shows for Fujirebio Diagnostics, Incorporated

$2,245,804.41: that is what Fujirebio Diagnostics, Incorporated reported in payments to 10 physicians and teaching hospitals during Program Year 2024, spread across 16 transactions ($140.4K per transaction, $224.6K per recipient). The company sits at rank #424 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 2 general-payment categories charted below, "Royalty or License" is the largest at $2.1M across 5 transactions, 97.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Fujirebio Diagnostics, Incorporated made 2 types of general payments. "Royalty or License" is the largest category at $2.1M, 97.9% of General Payments.

How Fujirebio Diagnostics, Incorporated divides its payments

Ranked by total dollars reported per category

1. Royalty or License$2.1M2. Consulting Fee$45.8K
Payment Type Amount Transactions
Royalty or License $2.1M 5
Consulting Fee $45.8K 5

Recipient Concentration in General Payments

The five largest recipient relationships account for $2,144,486.78 (100.0%) of $2,144,486.78 in this company's General Payments records across 4 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Fujirebio Diagnostics, Incorporated

The five named recipients with the highest reported General Payments from this company

Dana-Farber Cancer Institute$2.1MRobert Charles Knapp$26.3KRichard G. Moore$19.5KUniversity Of Washington Med…$10.0K
  1. 1

    Dana-Farber Cancer Institute

    $2,088,717.00 across 4 reported transactions

  2. 2

    Robert Charles Knapp

    $26,250.00 across 3 reported transactions

  3. 3

    Richard G. Moore

    $19,519.78 across 2 reported transactions

  4. 4

    University Of Washington Med Ctr

    $10,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Fujirebio Diagnostics, Incorporated's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Fujirebio Diagnostics, Incorporated.

Sonavex, Inc.

HHI 9490

Sensible Medical Innovations Inc

HHI 9459

Henry Schein, Inc.

HHI 9520

Varex Imaging Corporation

HHI 9523

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Fujirebio Diagnostics, Incorporated.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Fujirebio Diagnostics, Incorporated's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.